PMC:7441788 / 15107-15452 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T97","span":{"begin":114,"end":122},"obj":"Disease"}],"attributes":[{"id":"A97","pred":"mondo_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"rallel, double-blind, randomized, phase IIB clinical trial was performed in Brazil [49]. In this study, 81 severe COVID-19 patients were randomly divided into two groups: 41 patients received high-dose CQ (600 mg/2 times/day for 10 day) and 40 patients received low-dose CQ (450 mg/2 times on day 1 and then 450 mg/1 time/day for 4 days). The 13"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T171","span":{"begin":171,"end":173},"obj":"http://purl.obolibrary.org/obo/CLO_0053794"}],"text":"rallel, double-blind, randomized, phase IIB clinical trial was performed in Brazil [49]. In this study, 81 severe COVID-19 patients were randomly divided into two groups: 41 patients received high-dose CQ (600 mg/2 times/day for 10 day) and 40 patients received low-dose CQ (450 mg/2 times on day 1 and then 450 mg/1 time/day for 4 days). The 13"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T198","span":{"begin":202,"end":204},"obj":"Chemical"},{"id":"T199","span":{"begin":271,"end":273},"obj":"Chemical"}],"attributes":[{"id":"A198","pred":"chebi_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A199","pred":"chebi_id","subj":"T199","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"}],"text":"rallel, double-blind, randomized, phase IIB clinical trial was performed in Brazil [49]. In this study, 81 severe COVID-19 patients were randomly divided into two groups: 41 patients received high-dose CQ (600 mg/2 times/day for 10 day) and 40 patients received low-dose CQ (450 mg/2 times on day 1 and then 450 mg/1 time/day for 4 days). The 13"}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T123","span":{"begin":202,"end":204},"obj":"Chemical"},{"id":"T124","span":{"begin":271,"end":273},"obj":"Chemical"}],"attributes":[{"id":"A123","pred":"chebi_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A124","pred":"chebi_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"}],"text":"rallel, double-blind, randomized, phase IIB clinical trial was performed in Brazil [49]. In this study, 81 severe COVID-19 patients were randomly divided into two groups: 41 patients received high-dose CQ (600 mg/2 times/day for 10 day) and 40 patients received low-dose CQ (450 mg/2 times on day 1 and then 450 mg/1 time/day for 4 days). The 13"}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T100","span":{"begin":114,"end":122},"obj":"Species"}],"attributes":[{"id":"A100","pred":"ncbi_taxonomy_id","subj":"T100","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"rallel, double-blind, randomized, phase IIB clinical trial was performed in Brazil [49]. In this study, 81 severe COVID-19 patients were randomly divided into two groups: 41 patients received high-dose CQ (600 mg/2 times/day for 10 day) and 40 patients received low-dose CQ (450 mg/2 times on day 1 and then 450 mg/1 time/day for 4 days). The 13"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T111","span":{"begin":89,"end":170},"obj":"Sentence"},{"id":"T112","span":{"begin":171,"end":338},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"rallel, double-blind, randomized, phase IIB clinical trial was performed in Brazil [49]. In this study, 81 severe COVID-19 patients were randomly divided into two groups: 41 patients received high-dose CQ (600 mg/2 times/day for 10 day) and 40 patients received low-dose CQ (450 mg/2 times on day 1 and then 450 mg/1 time/day for 4 days). The 13"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"764","span":{"begin":123,"end":131},"obj":"Species"},{"id":"765","span":{"begin":174,"end":182},"obj":"Species"},{"id":"766","span":{"begin":244,"end":252},"obj":"Species"},{"id":"771","span":{"begin":202,"end":204},"obj":"Chemical"},{"id":"772","span":{"begin":271,"end":273},"obj":"Chemical"},{"id":"777","span":{"begin":114,"end":122},"obj":"Disease"}],"attributes":[{"id":"A764","pred":"pubann:denotes","subj":"764","obj":"Tax:9606"},{"id":"A765","pred":"pubann:denotes","subj":"765","obj":"Tax:9606"},{"id":"A766","pred":"pubann:denotes","subj":"766","obj":"Tax:9606"},{"id":"A771","pred":"pubann:denotes","subj":"771","obj":"MESH:D002738"},{"id":"A772","pred":"pubann:denotes","subj":"772","obj":"MESH:D002738"},{"id":"A777","pred":"pubann:denotes","subj":"777","obj":"MESH:C000657245"}],"text":"rallel, double-blind, randomized, phase IIB clinical trial was performed in Brazil [49]. In this study, 81 severe COVID-19 patients were randomly divided into two groups: 41 patients received high-dose CQ (600 mg/2 times/day for 10 day) and 40 patients received low-dose CQ (450 mg/2 times on day 1 and then 450 mg/1 time/day for 4 days). The 13"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T90","span":{"begin":114,"end":122},"obj":"Disease"}],"attributes":[{"id":"A90","pred":"mondo_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"rallel, double-blind, randomized, phase IIB clinical trial was performed in Brazil [49]. In this study, 81 severe COVID-19 patients were randomly divided into two groups: 41 patients received high-dose CQ (600 mg/2 times/day for 10 day) and 40 patients received low-dose CQ (450 mg/2 times on day 1 and then 450 mg/1 time/day for 4 days). The 13"}

{"project":"LitCovid-PubTator","denotations":[{"id":"764","span":{"begin":123,"end":131},"obj":"Species"},{"id":"765","span":{"begin":174,"end":182},"obj":"Species"},{"id":"766","span":{"begin":244,"end":252},"obj":"Species"},{"id":"771","span":{"begin":202,"end":204},"obj":"Chemical"},{"id":"772","span":{"begin":271,"end":273},"obj":"Chemical"},{"id":"777","span":{"begin":114,"end":122},"obj":"Disease"}],"attributes":[{"id":"A764","pred":"tao:has_database_id","subj":"764","obj":"Tax:9606"},{"id":"A765","pred":"tao:has_database_id","subj":"765","obj":"Tax:9606"},{"id":"A766","pred":"tao:has_database_id","subj":"766","obj":"Tax:9606"},{"id":"A771","pred":"tao:has_database_id","subj":"771","obj":"MESH:D002738"},{"id":"A772","pred":"tao:has_database_id","subj":"772","obj":"MESH:D002738"},{"id":"A777","pred":"tao:has_database_id","subj":"777","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"rallel, double-blind, randomized, phase IIB clinical trial was performed in Brazil [49]. In this study, 81 severe COVID-19 patients were randomly divided into two groups: 41 patients received high-dose CQ (600 mg/2 times/day for 10 day) and 40 patients received low-dose CQ (450 mg/2 times on day 1 and then 450 mg/1 time/day for 4 days). The 13"}

{"project":"LitCovid-sentences","denotations":[{"id":"T111","span":{"begin":89,"end":170},"obj":"Sentence"},{"id":"T112","span":{"begin":171,"end":338},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"rallel, double-blind, randomized, phase IIB clinical trial was performed in Brazil [49]. In this study, 81 severe COVID-19 patients were randomly divided into two groups: 41 patients received high-dose CQ (600 mg/2 times/day for 10 day) and 40 patients received low-dose CQ (450 mg/2 times on day 1 and then 450 mg/1 time/day for 4 days). The 13"}